Literature DB >> 11292879

Increasing threat of Gram-negative bacteria.

G W Waterer1, R G Wunderink.   

Abstract

The widespread use of broad-spectrum antibiotics has led to emergence of antibiotic-resistant strains of many Gram-negative organisms. This problem is particularly serious in critically ill patients, especially those with ventilator-associated pneumonia. Extensive antibiotic resistance has developed in Gram-negative bacteria, due both to innate resistance in some species and the fact that they are highly adept at acquiring antibiotic-resistant determinants from each other. Antibiotic resistance develops through the following three basic mechanisms: alteration of the drug target, prevention of drug access to the target (including actively removing the drug from the bacteria), and drug inactivation. Certain Gram-negative microorganisms are particular problems in the intensive care unit, including Pseudomonas aeruginosa, Acinetobacter spp., Stenotrophomonas maltophilia, and the Enterobacteriaceae. The combination of an increasing population at risk, and the natural virulence and adaptability of Gram-negative bacteria guarantees that critical care physicians will face a persistent and increasing challenge from these pathogens.

Entities:  

Mesh:

Year:  2001        PMID: 11292879     DOI: 10.1097/00003246-200104001-00004

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  18 in total

1.  Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard; Jason Valentine
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

2.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Authors:  Phillip J Bergen; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Epidemiology of infections due to extended-spectrum Beta-lactamase-producing bacteria in a pediatric intensive care unit.

Authors:  Kim W Benner; Priya Prabhakaran; Autumn S Lowros
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

5.  Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational In Vivo Rat Model.

Authors:  Jiajun Liu; Gwendolyn M Pais; Sean N Avedissian; Annette Gilchrist; Andrew Lee; Nathaniel J Rhodes; Alan R Hauser; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

6.  Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Authors:  Taylor M Patek; Chengwen Teng; Kaitlin E Kennedy; Carlos A Alvarez; Christopher R Frei
Journal:  Drug Saf       Date:  2020-01       Impact factor: 5.606

7.  Hydrolyzable Poly[Poly(Ethylene Glycol) Methyl Ether Acrylate]-Colistin Prodrugs through Copper-Mediated Photoinduced Living Radical Polymerization.

Authors:  Chongyu Zhu; Elena K Schneider; Vasiliki Nikolaou; Tobias Klein; Jian Li; Thomas P Davis; Michael R Whittaker; Paul Wilson; Kristian Kempe; Tony Velkov; David M Haddleton
Journal:  Bioconjug Chem       Date:  2017-07-07       Impact factor: 4.774

8.  Variables determining the development of colistin-associated renal impairment.

Authors:  Bahadır Ceylan; Müdür Taniş; Muhammed Emin Akkoyunlu; Ahmet Çınar; Ayşe Ruhkar Kurt; Yasemin Akkoyunlu; Didem Ozkan; Hatice Kutbay Ozcelik; Turan Aslan; Muzaffer Fincancı; Şule Vatansever; Kadir İdin; Emine Guler; Harun Uysal
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

9.  Retargeting R-type pyocins to generate novel bactericidal protein complexes.

Authors:  Steven R Williams; Dana Gebhart; David W Martin; Dean Scholl
Journal:  Appl Environ Microbiol       Date:  2008-04-25       Impact factor: 4.792

10.  In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Céline Vidaillac; Steve N Leonard; Helio S Sader; Ronald N Jones; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.